The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis

Bibliography

• BROWN RH, MEININGER V, SWASH M: Amyotrophic lateral sclerosis. Martin Dunitz, London (2000).
   Google Scholar
• BRUIJN LI, MILLER TM,
   Google Scholar
• CLEVELAND DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann. Rev Neurosci. (2004) 27:723–749.
   PubMed Web of Science ®Google Scholar
• SHAW CE, AL-CHALABI A, LEIGH N: Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr. Neurol Neurasci. Rep. (2001) 1:69–76.
   PubMedGoogle Scholar
• ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
   PubMed Web of Science ®Google Scholar
• DOBLE A: The pharmacology and mechanism of action of riluzole. Neurology (1996) 47\(Suppl. 4):5233–5241.
   Google Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl. I Med. (1994) 330:585–591.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN et al: A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology (1996) 47\(Suppl. 4):S242–S250.
   Google Scholar
• COURATIER P, DRUET-CABANAC M, TRUONG CT et al: Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS. Rev. Neurol (2000) 156:357–363.
   PubMedGoogle Scholar
• TURNER MR, BAKKER M, SHAM P et al: Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Motor Neuron. Disord. (2002) 3:15–21.
   PubMed Web of Science ®Google Scholar
• TRAYNOR BJ, ALEXANDER M, CORR B et al.: An outcome study of riluzole in amyotrophic lateral sclerosis - a population-based study in Ireland, 1996-2000. J. Neurol (2003) 250:473–479.
   PubMed Web of Science ®Google Scholar
• LEIGH PN, SWASH M, IWASAKI Y et a/.: Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) 5:84–98.
   Google Scholar
• MILLER RG, MITCHELL JD, LYON M, MOORE DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev (2002) 2:CD001447.
   Google Scholar
• LE LIBOUX A, LEFEBVRE P, LE ROUX Yet al.: Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J. Chi]. Pharmacol (1997) 37:820–827.
   Google Scholar
• GROENEVELD GJ, VAN KAN HJ, KALMIJN S et al.: Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology (2003) 61:1141–1143.
   PubMed Web of Science ®Google Scholar
• SANDERINK GJ, BOURNIQUE B, STEVENS J et al.: Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. Pharmacol Exp. Ther. (1997) 282:1465–1472.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN et al: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 347:1425–1431.
   PubMed Web of Science ®Google Scholar
• REMY AJ, CAMU W, RAMOS J et al: Acute hepatitis after riluzole administration. Hepatol (1999) 30:527–530.
   Web of Science ®Google Scholar
• CASTELLS LI, GAMEZ J, CERVERA C, GUARDIA J: Icteric toxic hepatitis associated with riluzole. Lancet (1998) 351:648.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, DIB M, DOPPLER Vet al.: Tolerance of riluzole in a Phase IIIb clinical trial. Therapie (2002) 57:65–71.
   Google Scholar
• DEBOVE C, ZEISSER P, SALZMAN PMet al: The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. (2001) 2:153–158.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2002) 3:23–29.
   PubMed Web of Science ®Google Scholar
• PONGRATZ D, NEUNDORFER B, FISCHER W: German open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). Neurol Sci. (2000) 180:82–85.
   Google Scholar
• BENSIMON G, LACOMBLEZ L, DELUMEAU JC et al: A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Neurol (2002) 249:609–615.
   Web of Science ®Google Scholar
• MEININGER V, BENSIMON G, BRADLEY WR et al: Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two Phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) 5:107–117.
   PubMed Web of Science ®Google Scholar
• DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2001) 2:9–18.
   PubMed Web of Science ®Google Scholar
• LE LIBOUX A, CACHIA JP, KIRKESSELI S et al.: A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J. Pharmacol (1999) 39:480–486.
   Google Scholar
• BRUNO R, VIVIERN, MONTAY G et al: Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin. Pharmacol Ther. (1997) 62:518–526.
   PubMed Web of Science ®Google Scholar
• HAAS JF: The tolerability and adverse event profile of riluzole. Rev Contemp. Pharmacother. (1998) 8:265–273.
   Google Scholar
• RESTIVO DA, BIANCONI C, RAVENNI R, DE GRANDIS D: ALS and myasthenia: An unusual association in a patient treated with riluzole. Muscle Nerve. (2000) 23:294–295.
   PubMed Web of Science ®Google Scholar
• DRORY VE, SIDI I, KORCZYN AD: Riluzole-induced pancreatitis. Neurology (1999) 52:892–893.
   PubMed Web of Science ®Google Scholar
• POLONI TE, ALIMONTI D, MONTAGNA G et al: Renal tubular impairment during riluzole therapy. Neurology (1999) 52:670.
   PubMed Web of Science ®Google Scholar
• NORTH WA, KHAN AM, YAMASE HT, SPORN JR: Reversible granulocytopenia in association with riluzole therapy. Ann. Pharmacother. (2000) 34:322–324.
   PubMed Web of Science ®Google Scholar
• VIALLON A, PAGE Y, BERTRAND JC: Methemoglobinemia due to riluzole. N Engl. J. Med. (2000) 343:665–666.
   PubMed Web of Science ®Google Scholar
• RODRIGO L, MORENO M, CALLEJA S et al.: Riluzole-induced acute pancreatitis. Am. J. Castroenterol (2001) 96:2268–2269.
   PubMed Web of Science ®Google Scholar
• WEBER G, BITTERMAN H: Riluzole-induced neutropenia. Neurology (2004) 62:1648.
   PubMed Web of Science ®Google Scholar
• WOOLF A, CARSTAIRS SD, TANEN DA: Riluzole-induced methemoglobinemia. Ann. Emerg. Med. (2004) 43:294.
   PubMed Web of Science ®Google Scholar
• SCELSA SN, KHAN I: Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Ear: Nemo]. (2000) 43:224–227.
   PubMed Web of Science ®Google Scholar
• MILLER RG, PETAJAN JH, BRYAN WW et al: A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. (1996) 39:256–260.
   PubMed Web of Science ®Google Scholar
• LAI EC, FELICE KJ, FESTOFF BW et al:Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology (1997) 49:1621–1630.
   Google Scholar
• CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456–464.
   PubMed Web of Science ®Google Scholar